Gemphire Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone734-245-1700
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees9
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Gemphire Therapeutics (NASDAQ:GEMP) Frequently Asked Questions
What is Gemphire Therapeutics' stock symbol?
Gemphire Therapeutics trades on the NASDAQ under the ticker symbol "GEMP."
How were Gemphire Therapeutics' earnings last quarter?
Gemphire Therapeutics Inc (NASDAQ:GEMP) issued its quarterly earnings results on Friday, March, 15th. The company reported ($0.26) EPS for the quarter, topping the Zacks' consensus estimate of ($0.41) by $0.15. View Gemphire Therapeutics' Earnings History.
When is Gemphire Therapeutics' next earnings date?
What is the consensus analysts' recommendation for Gemphire Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gemphire Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gemphire Therapeutics.
Has Gemphire Therapeutics been receiving favorable news coverage?
News headlines about GEMP stock have trended positive on Sunday, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Gemphire Therapeutics earned a news impact score of 2.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the immediate future. View News Stories for Gemphire Therapeutics.
Are investors shorting Gemphire Therapeutics?
Gemphire Therapeutics saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 678,400 shares, an increase of 12.4% from the June 30th total of 603,600 shares. Based on an average daily trading volume, of 251,900 shares, the days-to-cover ratio is presently 2.7 days. Approximately 6.6% of the company's stock are sold short. View Gemphire Therapeutics' Current Options Chain.
Who are some of Gemphire Therapeutics' key competitors?
Some companies that are related to Gemphire Therapeutics include Sierra Oncology (SRRA), Zafgen (ZFGN), Innovate Biopharmaceuticals (INNT), ContraFect (CFRX), DiaMedica Therapeutics (DMAC), AzurRx BioPharma (AZRX), Clearside Biomedical (CLSD), Sophiris Bio (SPHS), Akari Therapeutics (AKTX), Vistagen Therapeutics (VTGN), Aerpio Pharmaceuticals (ARPO), Sernova (SEOVF), Acerus Pharmaceuticals (ASPCF), Sienna Biopharmaceuticals (SNNA) and Citius Pharmaceuticals (CTXR).
What other stocks do shareholders of Gemphire Therapeutics own?
Who are Gemphire Therapeutics' key executives?
Gemphire Therapeutics' management team includes the folowing people:
- Dr. Charles L. Bisgaier, Co-Founder, Chairman & Chief Scientific Officer (Age 65)
- Dr. Steven R. Gullans, CEO, Pres, Director, Principal Financial Officer & Principal Accounting Officer (Age 66)
- Mr. Seth Reno, Chief Commercial Officer (Age 52)
- Mr. Jeffrey S. Mathiesen C.P.A., CPA, Consultant (Age 58)
- Ms. Amy Zaremba Rabourn, Director of Fin.
When did Gemphire Therapeutics IPO?
(GEMP) raised $30 million in an initial public offering (IPO) on Friday, August 5th 2016. The company issued 3,000,000 shares at $10.00 per share. Jefferies and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Roth Capital Partners were co-managers.
Who are Gemphire Therapeutics' major shareholders?
Gemphire Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include VHCP Management III LLC (5.59%), BlackRock Inc. (4.54%), VHCP Management II LLC (3.31%) and Vanguard Group Inc. (1.32%). View Institutional Ownership Trends for Gemphire Therapeutics.
Which major investors are selling Gemphire Therapeutics stock?
Which major investors are buying Gemphire Therapeutics stock?
How do I buy shares of Gemphire Therapeutics?
Shares of GEMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Gemphire Therapeutics' stock price today?
One share of GEMP stock can currently be purchased for approximately $0.5649.
How big of a company is Gemphire Therapeutics?
What is Gemphire Therapeutics' official website?
How can I contact Gemphire Therapeutics?
Gemphire Therapeutics' mailing address is 17199 N. LAUREL PARK DRIVE SUITE 401, LIVONIA MI, 48152. The company can be reached via phone at 734-245-1700 or via email at [email protected]
MarketBeat Community Rating for Gemphire Therapeutics (NASDAQ GEMP)
MarketBeat's community ratings are surveys of what our community members think about Gemphire Therapeutics and other stocks. Vote "Outperform" if you believe GEMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GEMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
